CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Valcyte (valganciclovir) — Coverage Criteria

Clinical coverage and authorization guidance for Valcyte (valganciclovir) for treatment and prevention of cytomegalovirus (CMV) across FDA-approved and compendial uses; applies to Neighborhood Health Plan of Rhode Island members managed under this policy.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyValcyte (valganciclovir) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization for up to 12 months when treating or preventing CMV and document that the member meets indication and approval criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsStandard authorization period

FDA-approvedFDA-approved uses

ListedCompendial uses

Coverage Criteria for Valcyte (valganciclovir)

Indications for valganciclovir that are not listed among the FDA-approved or compendial uses in this policy are considered experimental/investigational and are not medically necessary for coverage.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Responsibilities and Authorization Notes

Documentation Required

General documentation required

Providers must document in the medical record that the member meets all indication and approval criteria for the requested therapy and that no exclusion(s) to therapy are present. Documentation should include indication, transplant or HIV status when applicable, treatment history, relevant diagnostic test results, and treatment plan to support initial authorization and any reauthorization requests.

Include evidence member meets applicable indication (e.g., CMV disease, prophylaxis post-transplant, symptomatic congenital CMV, multicentric Castleman's disease HHV-8 positive).
Document absence of exclusions and any relevant compendial or FDA indication.
For reauthorization, document clinical response and ongoing need for therapy, and that member continues to meet criteria.

Denial Risk

Experimental / Investigational — not medically necessary

Indications not listed in the policy (including any uses outside the FDA-approved or compendial indications enumerated) are considered experimental or investigational and are not medically necessary. Prior authorization will be denied for unlisted/unsupported indications.

All compendial and FDA-approved indications listed in the policy are considered covered when criteria are met; all other indications = experimental/investigational and not medically necessary.

Prior Authorization

Authorization duration and reauthorization notes

Authorizations and reauthorizations are generally granted for up to 12 months for covered indications (including treatment or prevention post-transplant, CMV disease in HIV, symptomatic congenital CMV, and multicentric Castleman's disease HHV-8 positive). For reauthorization requests, providers must submit documentation showing the member continues to meet the applicable initial authorization criteria and the clinical rationale for continued therapy.

Standard authorization duration: up to 12 months for initial and continuation treatment when criteria are met.
Reauthorization: submit clinical progress notes demonstrating ongoing need and that member still meets criteria in Section II.
Specific scenarios with 12-month authorization include: induction/maintenance for CMV retinitis in HIV, CMV GI disease in HIV, prophylaxis or preemptive CMV prevention post solid organ or HSCT, treatment of CMV in solid organ transplant recipients, symptomatic congenital CMV, multicentric Castleman's disease HHV-8 positive.

Background on Valganciclovir (Valcyte)

Valganciclovir (Valcyte) is an oral antiviral prodrug of ganciclovir that is used to treat and prevent disease caused by cytomegalovirus (CMV). Typical clinical uses include treatment of CMV infection in transplant recipients, prevention of CMV infection post–solid organ or hematopoietic stem cell transplant, treatment of CMV gastrointestinal disease in HIV infection, and treatment of symptomatic congenital CMV; it is also used for CMV retinitis in AIDS and other compendial indications such as multicentric Castleman’s disease (HHV-8 positive).

Key Definitions

High-risk transplant (D+/R-) — donor positive / recipient negative CMV serostatus defined as high risk for CMV disease in transplant recipients

DefinitionDonor CMV seropositive / recipient CMV seronegative (D+/R-)

Clinical significanceDesignated as 'high risk' for CMV disease in transplant recipients

Applies toKidney, heart, and kidney–pancreas transplant patients (adult and pediatric specifications exist)

Policy contextUsed to determine eligibility for Valcyte (valganciclovir) prophylaxis per FDA‑approved indications

Age notesFDA indication includes pediatric kidney transplant (4 months–16 years) and heart transplant (1 month–16 years) patients at high risk